SEROPREVALENȚA ANTICORPILOR p-ANCA LA PACIENȚII CU RECTOCOLITÃ ULCEROHEMORAGICÃ ȘI LA RUDELE LOR DE GRADUL I

  • Elena TOADER Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • Cecilia DURNEA Institutul de Sãnãtate Publicã Iași
Keywords: pANCA, ULCERATIVE COLITIS, ELISA

Abstract

Perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) are
more common in patients with ulcerative colitis (UC) than in patients with Crohns disease
(CD), but its prevalence depends on the population being studied and the method employed for
its detection. Aim: To determinate the prevalence of p-ANCA in ulcerative colitis (UC) patients
and their first degree in NE Romania area. Material and method: In this study, we investigated
the prevalence of p-ANCA as detected by ELISA, in the serum of 44 patients with UC
and 22 first degree relatives. We also correlated the presence of this antibody with disease
activity and extent, extraintestinal complications and therapy. 26 healthy individuals comprised
the control group. Results: p-ANCA was detected in 11% of the patients with UC. Of the 5
p-ANCA positive UC patients, 1 case were found to have proctosigmoiditis, 1 cases had
left-sided colitis and 3 cases had pancolitis. There was no correlation between the presence of
this antibody and any of the studied clinical variables (extend disease, complication, family
disease, surgery). No person of the first degree and control group presented positive test.
Conclusions: The prevalence of p-ANCA in NE Romania patients with UC (11 %) is lower
than that in the Western population. The negativity of p-ANCA in all first degree relatives of
NE Romania UC patients should be further elucidated.

Author Biography

Elena TOADER, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Institutul de Gastroenterologie și Hepatologie Iași

References

1. Bossuyt X. Serologic markers in inflammatory bowel diseases. Clin Chem 2006; 52: 171-181.
2. Joossens S, Reinisch W, Veimeire S et al. The values of serologic markers in indeterminate colitisa
prospective follow-up study. Gastroenterol 2002; 122: 1242-1247.
3. Sandborn WJ, Loftus EV Jr, Colombel JF et al. Evaluation of serologic disease markers in a
population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis
2001; 7: 192-201.
4. Joossens S, Daperno M, Shums Z et al. Interassay and interobserver variability in the detection of antineutrophil
cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem 2004; 50: 1422-1425.
5. Kull K, Salupere R, Uibo R, Ots M, Salupere V. Antineutrophil cytoplasmic antibodies in Estonian
patiens with inflammatory bowel diseases: prevalence and diagnosis role. Hepato-Gastroenterol
1998; 45: 2132- 2137.
6. Ferrante M, Henckaerts L. Jonssens M et al. New serologic markers inflammatory bowel disease
are associated with complicated disease behaviour. Gut 2007; 56: 1394-1403.
7. Dubinski MC. Can serologic markers help determinate prognosis and guide therapy. Falk Symposium
172, 2010, 30.
8. Vernier G, Sendid B, Poulain D, Colombel JF. Relevance of serologic studies in inflammatory
bowel disease Curr Gastroenterol Rep 2004; 6 (6): 482-487.
9. Duerr RH, Neigut DA. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an
antineutrophil cytoplasmic antibody-positive subgroup. J Autoimmun 2000; 14 (1): 83-97.
10. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with
susceptibility to Crohn’s disease. Nature 2001; 411: 599-603.
11. Osangthamnont C, Manatsathit S, Pongprasopchai S et al. Antibodies to neutrophil cytoplasma
with ulcerative colitis and thei first-degree relatives in Thailand. J Gastroenterol Hepatol 2001; 16
(8): 866-871.
12. Shanahan F, Duerr RH, Roterr JI et al. Neutrophil antibodies in in ulcerative colitis : familial
agrregation and genetic heterogeneity. Gastroenterol 1992; 103:456-461.
13. Dotan I. New serologic markers for IBD diagnostic, The key to IBD:Treatment , diagnostic and
pathophysiology. Falk Symposium 172, 2010, 29.
14. MacDonald TT, Monteleone G. Immunity, inflammation and allergy in the gut. Science 2005;
307: 1920-1925
15. Guarner F. The intestinal flora in inflammatory bowel disease:normal or abnormal? Curr Opin
Gastroenterol 2005; 21: 414-418.
16. Seep E, Julge K, Vasar M et al. Intestinal microflora of Estonian and Swedish infant. Acta Paediatr
1997; 86: 956-961.
Published
2019-04-19
Section
INTERNAL MEDICINE - PEDIATRICS